Hengrui Pharma's Oral Antihypertensive Drug Olmesartan Medoxomil Tablets, with Annual Sales Exceeding RMB 300 Million, Gains NMPA Approval

Apr 23, 2024 20:30 CST Updated 20:30

Hengrui Pharmaceutical

Chemical Drug Manufacturer

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements. This article only introduces drugs related to medical health, not a recommendation of treatment plans (if involved), and does not represent the platform's position. Authorization is required for any article reprint.

Today, according to the official website of NMPA,Chengdu Hengrui Pharmaceutical Co., Ltd.Generic drugOlmesartan Medoxomil TabletsApproved for marketing and deemed to have passed the evaluation. According to statistics from PharmaCloud, the sales revenue of this product in China's hospital market exceeded 300 million yuan in 2022.

Screenshot Source: NMPA official website

Olmesartan Medoxomil TabletsThe original research company is Daiichi Sankyo Co., Ltd. of Japan. It is an angiotensin II antagonist used for the treatment of hypertension. It was successfully developed in 1991, approved for marketing in the United States in 2002, and Olmesartan Medoxomil Tablets were approved for marketing in China in 2006.(Product Name: Aotan).AfterOlmesartan Medoxomil and Hydrochlorothiazide Tablets(Product name: Fuaotan)、Olmesartan Medoxomil Capsules, Olmesartan Medoxomil and Amlodipine TabletsHave also been successively approved for marketing.

As a new generation of angiotensin receptor antagonist（ARB）As a class of antihypertensive drugs, Olmesartan Medoxomil is characterized by convenient administration, small dosage, and rapid onset. It is classified as a Class B medical insurance product in China and is listed as a commonly used antihypertensive drug in the "Chinese Guidelines for the Prevention and Treatment of Hypertension" (2018 Revised Edition) and the "Guidelines for Rational Use of Antihypertensive Drugs." According to data from PharmaCloud,Olmesartan Medoxomil TabletsIn 2022, the sales revenue of the in-hospital market in China exceeded 3 billion yuan, with a year-on-year increase of 20.35%.

Screenshot source:Pharmcube National Hospital Sales Database

Currently,Olmesartan Medoxomil TabletsTwenty pharmaceutical companies hold production licenses, of which 18, including Nanjing Chia Tai Tianqing, Chengdu Better Pharmaceutical, Yangtze River Pharmaceutical, and Qilu Pharmaceutical, have passed the evaluation. Nanjing Chia Tai Tianqing becomes the first to pass the evaluation and secures the first generic drug approval.

Screenshot source:PharmCube Approved Drugs Summary Database

In the field of generic drug layout, Zhejiang Huahai Pharmaceutical has also submittedOlmesartan Medoxomil TabletsThe generic applications are all under review and approval. In October 2022, Chengdu Hengrui Pharmaceutical Co., Ltd. submittedOlmesartan Medoxomil TabletsAccepted by the CDE, it successfully obtained NMPA approval for marketing on April 23, 2024, and was deemed to have passed the evaluation.

In addition, Chengdu Hengrui Pharmaceutical Co., Ltd. submittedEmpagliflozin Tablets, Rosuvastatin Calcium Tablets, Glucosamine Sulfate Capsules, Vildagliptin Tablets, Acarbose TabletsFive generic applications are under review, covering four major fields: digestive system and metabolic drugs, cardiovascular system drugs, musculoskeletal system drugs.

Screenshot source:PharmCube China Drug Evaluation Database

In addition to this approval and passing evaluationOlmesartan Medoxomil Tablets，Chengdu Hengrui Pharmaceutical Co., Ltd.Gliclazide Sustained-Release Tablets, Metformin Hydrochloride Sustained-Release Tablets, Cetirizine Hydrochloride Tablets, Amlodipine BesylateTabletFour varieties passed the evaluation.

END

This article is original. Please leave a message to obtain authorization for reprint.

Recent Popular Resource Acquisition

Reply to the keyword " in the backgroundReport", access dozens of exclusive reports produced by Yaorong Cloud
Reply to the keyword " in the backgroundCSCO", obtain 2023 CSCO guidelines
Reply to the keyword " in the backgroundASCO", Obtain 2023 ASCO Abstract by Cancer Type
Reply to the keyword "First Generic in 2023", obtain the list of first generic drugs approved in 2023
Reply to the keyword "Medical Insurance", Obtain the 2022 Medical Insurance Catalog

Contact us to experience more professional services from PharmaCloud.

WillDiscussion

CombineWork

GardenDistrict

TakeWu

Database

Consultation

Customization

Service

Media

Cooperation

ClickReadRead the Original Text, apply for a free trial of PharmaCloud Enterprise Edition!